Analysts expect GSK to report Q3 2026 revenue of £8.86 billion and core EPS of 50.4p, as the stock trades at 1,910.50 GBp compared to an analyst target of 2,172.91 GBp.
Investors are intensely focused on the performance of the Vaccines segment, particularly Shingrix and Arexvy sales, which face competitive pressures in the U.S. market.
The quarterly results will be significantly impacted by a £1.8 billion legal charge to settle the majority of outstanding Zantac litigation, resolving a primary concern for shareholders.
Growth in the HIV segment and specialty medicines remains key to the 'Accelerate Growth' strategy, even as integration costs from the $10.6 billion Nuvalent acquisition dampen short-term earnings.